Put CV Risks With Testosterone in Perspective
August 2023
New evidence will help clarify CV risk of testosterone replacement in men with hypogonadism.
Testosterone product labels caution about possible increased risk of heart attack and stroke. This stems from a 2015 FDA warning...based on small and observational trials with conflicting data.
Now a new study suggests transdermal 1.62% testosterone gel (AndroGel) daily for about 22 months does not increase risk of CV death, heart attack, or stroke more than placebo.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote